Home › Funds › Vestal Point Capital, LP › TSHA

Vestal Point Capital, LP position in TSHA

TAYSHA GENE THERAPIES INC · Health Care

Vestal Point Capital, LP reported holding 19,415,000 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q2 2026 13F filing — a position valued at US$132.2M, representing 3.09% of its reported portfolio and ranking #8 among its reported holdings. Vestal Point Capital, LP has disclosed TSHA holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)19.41M sh
Reported value held$132.22M
Portfolio Weight3.09%
First reportedQ2 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's TSHA position evolved

Vestal Point Capital, LP first disclosed a stake in TSHA in Q2 2025 at 3,000,000 shares (US$6.9M). The position peaked in Q2 2026 at 19,415,000 shares, worth US$132.2M. Across 5 filings, Vestal Point Capital, LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 19,415,000 shares valued at US$132.2M — an increase of 1,415,000 shares quarter over quarter.. Notable position changes include a 83% increase in Q3 2025 (shares rose 68% over the following quarter), a 150% increase in Q4 2025 (shares fell 19% over the following quarter), a 31% increase in Q1 2026 (shares rose 52% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 3.00M $6.93M New
Q3 2025 5.50M $17.98M Add
Q4 2025 13.75M $75.62M Add
Q1 2026 18.00M $80.46M Add
Q2 2026 19.41M $132.22M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TSHA and 13F data

TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 56 other funds we track also report a position in TSHA — the largest reported positions include Avoro Capital Advisors LLC (US$162.7M), RA CAPITAL MANAGEMENT, L.P. (US$160.4M), RTW INVESTMENTS, LP (US$92.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TSHA

All TSHA fund holders →

FAQ

How long has Vestal Point Capital, LP held TSHA?

Vestal Point Capital, LP has disclosed TSHA holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Vestal Point Capital, LP's current position in TSHA?

As of Q2 2026, Vestal Point Capital, LP holds 19.41M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $132.22M, representing 3.09% of its reported portfolio and ranking #8.

Has Vestal Point Capital, LP been buying or selling TSHA?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP increased its position in TSHA. The position peaked in Q2 2026 at 19.41M shares.

Which other funds hold TSHA?

Other major institutional holders of TSHA include Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., RTW INVESTMENTS, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.